CTOs on the Move

RayzeBio

www.rayzebio.com

 
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rayzebio.com
  • 5505 Morehouse Drive Suite 300
    San Diego, CA USA 92121
  • Phone: 858.257.3449

Executives

Name Title Contact Details
Tarun Patel
Vice President, Head of Quality Profile

Funding

RayzeBio raised $105M on 12/08/2020
RayzeBio raised $45M on 10/14/2020
RayzeBio raised $108M on 06/15/2021

Similar Companies

Medical Business Resources

Medical Business Resources, Inc., established in 1994 as a medical billing service, offers a cost effective solution to the complexities of medical practice administration. Our services allow providers to focus upon delivering health care with the confidence that administrative support services are in place.

Poseida

Poseida Therapeutics is a clinical-stage biotechnology company translating best-in-class technology into lifesaving cell and gene therapies for patients with high unmet medical need. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as in vivo gene therapies for orphan genetic diseases. These cell therapies and the gene therapies soon to come are products of our proprietary suite of industry-leading gene engineering technologies, including the piggyBac® DNA Modification System, Cas-CLOVER™ and TAL-CLOVER™ site-specific nucleases.

Lexaria Bioscience

Lexaria Bioscience Corp. has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds. Lexaria has multiple patents pending and granted in over 40 countries around the world and was granted its first patent in the USA in October, 2016. Lexaria`s technology provides increases of up to 10x in intestinal absorption rates; more rapid delivery to the bloodstream with effects often within 15-20 minutes; and important taste-masking benefits, for orally administered bioactive molecules including but not limited to cannabinoids, vitamins, NSAIDs, and nicotine.

ACGT DNA Technologies

ACGT DNA Technologies is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DMC

DMC is leading the low cost sustainable transformation of multiple product markets.